John Bencich
2016
In 2016, John Bencich earned a total compensation of $365.7K as Executive Vice President and Chief Financial Officer and Chief Operating Officer at OncoGenex Pharmaceuticals, a 11% decrease compared to previous year.
Compensation breakdown
| Option Awards | $58,200 |
|---|---|
| Salary | $307,500 |
| Total | $365,700 |
Bencich received $307.5K in salary, accounting for 84% of the total pay in 2016.
Bencich also received $58.2K in option awards.
Rankings
In 2016, John Bencich's compensation ranked 12,187th out of 14,075 executives tracked by ExecPay. In other words, Bencich earned more than 13.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,187 out of 14,075 | 13th |
Division Manufacturing | 4,778 out of 5,489 | 13th |
Major group Chemicals And Allied Products | 1,703 out of 1,895 | 10th |
Industry group Drugs | 1,382 out of 1,538 | 10th |
Industry In Vitro and In Vivo Diagnostic Substances | 52 out of 65 | 20th |
Source: SEC filing on September 21, 2017.
Bencich's colleagues
We found two more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2016.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019